| 0.1018 0 (0%) | 03-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.12  |
1-year : | 0.15 |
| Resists | First : | 0.1 |
Second : | 0.12 |
| Pivot price | 0.08 |
|||
| Supports | First : | 0.06 | Second : | 0.05 |
| MAs | MA(5) : | 0.08 |
MA(20) : | 0.08 |
| MA(100) : | 0.15 |
MA(250) : | 0.56 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 16.3 |
D(3) : | 21.1 |
| RSI | RSI(14): 39.4 |
|||
| 52-week | High : | 2.14 | Low : | 0.06 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ OBSV ] has closed above bottom band by 19.1%. Bollinger Bands are 77.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.1 - 0.1 | 0.1 - 0.1 |
| Low: | 0.08 - 0.08 | 0.08 - 0.08 |
| Close: | 0.08 - 0.08 | 0.08 - 0.08 |
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.
Mon, 08 Apr 2024
Head-To-Head Survey: Abbott Laboratories (NYSE:ABT) vs. ObsEva (NASDAQ:OBSV) - Defense World
Wed, 27 Mar 2024
StockNews.com Initiates Coverage on ObsEva (NASDAQ:OBSV) - Defense World
Wed, 15 Mar 2023
ObsEva to delist from Nasdaq next week with eye on consolidating Swiss ops - Seeking Alpha
Wed, 15 Mar 2023
ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The ... - Yahoo Finance
Fri, 24 Feb 2023
ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland - GlobeNewswire
Fri, 24 Feb 2023
OBSV stock crashes on plans to delist from Nasdaq (NASDAQ:OBSV) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 108 (M) |
| Held by Insiders | 9.352e+007 (%) |
| Held by Institutions | 2 (%) |
| Shares Short | 707 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.606e+007 |
| EPS Est Next Qtrly | -0.65 |
| EPS Est This Year | -2.47 |
| EPS Est Next Year | -2.49 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 240.7 % |
| Return on Equity (ttm) | -50.3 % |
| Qtrly Rev. Growth | 3.71e+006 % |
| Gross Profit (p.s.) | -127.17 |
| Sales Per Share | -558.18 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -44 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | -1.88 |
| Dividend | 0 |
| Forward Dividend | 719290 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|